Treatment progress of splenic marginal zone lymphoma
10.3760/cma.j.cn115356-20190911-00181
- VernacularTitle:脾边缘区淋巴瘤的治疗进展
- Author:
Fengdi WANG
1
;
Chun ZHANG
Author Information
1. 华中科技大学同济医学院附属协和医院血液病研究所，武汉 430022
- From:
Journal of Leukemia & Lymphoma
2020;29(5):313-316
- CountryChina
- Language:Chinese
-
Abstract:
Splenic marginal zone lymphoma (SMZL) is a rare indolent B-cell lymphoma. Due to its rarity and the lack of large-scale prospective randomized trials of SMZL, the treatment of SMZL is mainly based on therapy regimens of other indolent lymphomas and expert consensus. Asymptomatic patients can wait and watch, while the traditional treatments of symptomatic patients include splenectomy and chemotherapy alone. Rituxmab monotherapy has become the new first-line option and been widely used because of its good efficacy over the last decades. With the further understanding of molecular etiology of various lymphomas, some novel target agents are under clinical trials in low-grade lymphoma including small amount of SMZL patients. This review mainly discusses the treatment progress of SMZL.
